News
Eli Lilly is a global healthcare giant, generating strong growth from a diverse portfolio of blockbuster medications. Viking ...
23h
Barchart on MSNEli Lilly vs. Novo Nordisk: Which Stock Is the Winner of the Weight-Loss Drug Boom?The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...
A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...
If you’re struggling with weight, you’re not alone. Around 42 percent of American adults have obesity. In addition to ...
If you are looking to get a weight loss drug but lack insurance coverage, telehealth websites such as Ro, Hers and Mochi Health sell GLP-1 drugs for lower prices than what you’d pay at a pharmacy, ...
When the Food and Drug Administration (FDA) approved Byetta (exenatide) in 2005, doctors thought it was just approving the ...
The findings presented at a conference in Chicago found a slightly lower risk of obesity-related cancers when adults with ...
The report also underscored the importance of maintaining muscle mass and bone density while losing weight. Since weight loss ...
Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...
As the Food and Drug Administration clamps down on off-brand weight loss medications, Seattle-area residents are stocking up ...
Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results